|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines显示文摘 | J. Panes Y. Bouhnik W. Reinisch J. Stoker S.A. Taylor D.C. Baumgart S. Danese S. Halligan B. Marincek C. Matos L. Peyrin-Biroulet J. Rimola G. Rogler G. van Assche S. Ardizzone A. Ba-Ssalamah M.A. Bali D. Bellini L. Biancone F. Castiglione R. Ehehalt R. G | 2013 | Journal of Crohn’s and Colitis2013，，7： | 2 |
| 2 | Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines显示文摘 | J. Panes Y. Bouhnik W. Reinisch J. Stoker S.A. Taylor D.C. Baumgart S. Danese S. Halligan B. Marincek C. Matos L. Peyrin-Biroulet J. Rimola G. Rogler G. van Assche S. Ardizzone A. Ba-Ssalamah M.A. Bali D. Bellini L. Biancone F. Castiglione R. Ehehalt R. G | 2013 | Journal of Crohn’s and Colitis2013，，7： | 1 |
| 3 | OC.06.3 ADALIMUMAB IN ACTIVE ULCERATIVE COLITIS: A “REAL-LIFE” OBSERVATIONAL STUDY显示文摘 | A. Armuzzi L. Biancone M. Daperno A. Coli V. Annese S. Ardizzone P. Balestrieri F. Bossa F. Castiglione M. Cicala S. Danese R. D’Incà P. Dulbecco G. Feliciangeli W. Fries S. Genise P. Gionchetti S. Gozzi A. Kohn R. Lorenzetti M. Milla S. Onali A. Orlando | 2012 | Digestive and Liver Disease2012，，： | 1 |
| 4 | Unsedated transnasal versus transoral sedated upper gastrointestinal endoscopy: A one-series prospective study on safety and patient acceptability显示文摘 | I. Stroppa E. Grasso O.A. Paoluzi C. Razzini C. Tosti F. Andrei L. Biancone G. Palmieri F. Romeo F. Pallone | 2008 | Digestive and Liver Disease2008，，9： | 1 |
| 5 | P422 Outpatient anal exploration and fistula treatment in Crohn’s disease patients with peri-anal disease. Study of feasibility显示文摘 | R. Scaramuzzo E. Iaculli C. Fiorani L. Biancone T. Giorgia D.C. Sara A. Gaspari G. Sica | 2013 | Journal of Crohn’s and Colitis2013，，： | 1 |
| 6 | 局部注射英夫利昔单抗治疗克罗恩病的术后复发显示文摘Background: Local injection of infliximab in Crohn’s disease (CD) lesions may reduce the risk of rare side effects, reduce the dose, and increase the efficacy of the drug. The objective was to prospectively assess the feasibility and the safety of local injection of infliximab for the postoperative recurrence of patients with CD who were followed for at least 1 year. Methods: In a pilot, open-label study, 8 patients with CD (3 men; median age 48 years, range 35- 82 years) undergoing ileocolonoscopy were prospectively enrolled. Inclusion criteria included the following: (1) localized (< 5 cm) recurrence, (2) inflammatory pattern, and (3) clinically inactive CD. At the first endoscopy, lesions were injected with infliximab (median, 30 mg; range, 8- 60 mg); a control endoscopy was performed at 2 weeks in 4 patients (3 received a second injection followed by a control endoscopy at 6 weeks) and at 4 weeks in 4 patients (2 received a second injection followed by a control endoscopy at 8 weeks). Observations: No patients showed side effects or clinical relapse in the short term and the long term (median follow-up, 20 months; range, 14- 21 months). Endoscopic score improved in 3/8 patients. The histologic scores were reduced in 4 patients, worsened in 3, and were unchanged in one patient with CD. Conclusions: Local injection of infliximab into patients with CD recurrence is feasible and safe, requiring a low dose. Present findings suggest the need of placebo-controlled trials to assess the efficacy of this new and safe procedure in subgroups of patients with CD. | Biancone L. Cretella M. Tosti C. 王晓君(译) 郑世成(校) | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，8： | 1 |
| 7 | Endoscopic vs ultrasonographic findings related to Crohn’s Disease recurrence: A prospective longitudinal study at 3<ce:hsp sp='0.25'/>years显示文摘 | S. Onali E. Calabrese C. Petruzziello F. Zorzi G.S. Sica E. Lolli M. Ascolani G. Condino F. Pallone L. Biancone | 2010 | Journal of Crohn’s and Colitis2010，，3： | 1 |
| 8 | Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection显示文摘 | F. Morisco F. Castiglione A. Rispo T. Stroffolini S. Sansone R. Vitale M. Guarino L. Biancone A. Caruso R. D’Inca R. Marmo A. Orlando G. Riegler L. Donnarumma S. Camera F. Zorzi S. Renna V. Bove G. Tontini M. Vecchi N. Caporaso | 2012 | J Viral Hepat2012，，3： | 1 |
| 9 | Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines显示文摘 | J. Panes Y. Bouhnik W. Reinisch J. Stoker S.A. Taylor D.C. Baumgart S. Danese S. Halligan B. Marincek C. Matos L. Peyrin-Biroulet J. Rimola G. Rogler G. van Assche S. Ardizzone A. Ba-Ssalamah M.A. Bali D. Bellini L. Biancone F. Castiglione R. Ehehalt R. G | 2013 | Journal of Crohn’s and Colitis2013，，： | 1 |
| 10 | 英福利昔单抗与克罗恩病患者新发肿瘤的关系:一项多中心配对研究显示文摘Background and aims: The widespread use of anti-tumour necrosis factor αantibody (Infliximab) in Crohn’s disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95%confidence interval 0.46-3.84); p = 0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p = 0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin’s lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40-70 years) v 45 (27-72); p = 0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab. | Biancone L. Orlando A. Kohn A. 刘丽娜(译) 王顺涛(校) | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员